News | January 24, 2014

CorMatrix Cardiovascular Receives U.S. Patent for Injectable Biomaterial

CorMatrix Cardiovascular Extracellular Matrix ECM Bioscaffold
January 24, 2014 — CorMatrix Cardiovascular Inc. received a patent for an augmented injectable extracellular matrix (ECM) bioscaffold. 
The augmented ECM bioscaffold induces stem cell proliferation and differentiation of stem cells into cardiomyocytes, and, thereby, angiogenesis and remodeling of cardiovascular tissue.
U.S. Patent No. 8,568,761 is based on one of multiple pending U.S. applications with claims directed toward ECM bioscaffolds that are augmented with a variety of bioactive components, such as TGF-2, TGF-? and DNA.
“Capturing and directing stem cell function for truly regenerating tissues requires the appropriate microenvironment, not just stem cells,” said Robert Matheny, M.D., a cardiovascular surgeon and chief scientific officer for CorMatrix. “The future of regenerative therapy will be directed toward enhancing our effective matrices with factors that fully capture and augment regeneration.”
CorMatrix has U.S. clearance and CE marking for its ECM technology as an implant for pericardial closure, cardiac tissue repair and carotid repair. It plans to initiate human safety trials for heart failure in Europe early in 2014 with its formula and device for application of the ECM. 
Background of Extracellular Matrix (ECM) Biomaterial
The decellularized matrix material serves as a bioscaffold to allow vascular ingrowth from adjacent tissues to deliver progenitor cells and nutrients to the matrix, which then differentiate into tissue-specific cells and structures. The ECM material is gradually replaced as the patient’s own cells reinforces and rebuilds the diseased or damaged site. During repair, the matrix is naturally degraded and resorbed, leaving remodeled functional tissue where damaged or injured tissue may be expected. 
For more information:

Related Content

Renovacor Closes $11 Million Series A Financing for New Cardiovascular Gene Therapy
News | Stem Cell Therapies | August 22, 2019
August 22, 2019 — Renovacor Inc, a preclinical-stage biopharmaceutical company, announced the successful completion o
Placental Stem Cells Can Regenerate the Heart After Heart Attack
News | Stem Cell Therapies | May 20, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta...
ProxiCor Extracellular Matrix Reduces Complications, Readmissions Following Pericardial Reconstruction
News | Stem Cell Therapies | April 19, 2019
Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal of...
FDA Releases Final Guidances on Regenerative Medicine Therapies
News | Stem Cell Therapies | March 04, 2019
The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding regenerative medicine...
Heart Muscle Cells Created From Stem Cells Beat in Sync
News | Stem Cell Therapies | February 01, 2019
A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a...
FDA Clamps Down on Unapproved Stem Cell Therapies
News | Stem Cell Therapies | December 20, 2018
December 20, 2018 — The U.S.
Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...